West Pharmaceutical Services (WST) 10-Q 1 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014
Document and Entity Information [Abstract]	'
Entity Registrant Name	'WEST PHARMACEUTICAL SERVICES INC
Entity Central Index Key	'0000105770
Current Fiscal Year End Date	'--12-31
Entity Well-known Seasoned Issuer	'Yes
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	70,764,711
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q2
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	30-Jun-14

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net sales	$368.90	$344.50	$715.70	$683.90
Cost of goods and services sold	247.1	233.6	487.5	461.3
Gross profit	121.8	110.9	228.2	222.6
Research and development	9.9	9.5	19.9	18.6
Selling, general and administrative expenses	57.5	59.7	113.9	118.7
Other expense (income) (Note 11)	0.3	-0.8	1	-0.6
Operating profit	54.1	42.5	93.4	85.9
Loss on debt extinguishment	0	0	0	0.2
Interest expense	4.2	4.1	8.2	8.7
Interest income	0.5	0.4	0.9	1
Income before income taxes	50.4	38.8	86.1	78
Income tax expense	14	10.3	23.8	18.9
Equity in net income of affiliated companies	1.2	1.7	2.4	2.8
Net income	$37.60	$30.20	$64.70	$61.90
Net income per share:	'	'	'	'
Basic (in dollars per share)	$0.53	$0.44	$0.92	$0.90
Diluted (in dollars per share)	$0.52	$0.43	$0.89	$0.88
Weighted average shares outstanding:	'	'	'	'
Basic (in shares)	70.8	69.5	70.7	69.2
Diluted (in shares)	72.4	70.8	72.4	70.6
Dividends declared per share	$0.10	$0.10	$0.20	$0.19

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$37.60	$30.20	$64.70	$61.90
Other comprehensive (loss) income, net of tax:	'	'	'	'
Foreign currency translation adjustments	-1.5	-0.8	-3.3	-19.1
Defined benefit pension and other postretirement plan adjustments, net of tax of $0, $0.7, $0.2 and $1.8, respectively	0.1	1.1	0.3	3.2
Net gains on derivatives, net of tax of $0.2, $0.5, $0.4 and $0.1, respectively	0.5	0.7	0.7	0.4
Other comprehensive (loss) income, net of tax	-0.9	1	-2.3	-15.5
Comprehensive income	$36.70	$31.20	$62.40	$46.40

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Defined benefit pension and other postretirement plan adjustments, tax	$0	$0.70	$0.20	$1.80
Net gains on derivatives, tax	$0.20	$0.50	$0.40	$0.10

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$226.70	$230
Accounts receivable, net	209.6	185.7
Inventories	187.9	176.9
Deferred income taxes	16.8	15.9
Other current assets	44.4	42.2
Total current assets	685.4	650.7
Property, plant and equipment	1,402.30	1,369
Less accumulated depreciation and amortization	693.1	657.3
Property, plant and equipment, net	709.2	711.7
Investments in affiliated companies	60.4	60.9
Goodwill	114	114.2
Deferred income taxes	65.5	61.8
Intangible assets, net	46.1	48.3
Other noncurrent assets	24.1	24
Total Assets	1,704.70	1,671.60
Current liabilities:	'	'
Notes payable and other current debt	2.2	2.2
Accounts payable	94.5	108
Pension and other postretirement benefits	2.2	2.2
Accrued salaries, wages and benefits	51.7	59.1
Income taxes payable	15	14.3
Other current liabilities	55.6	51.1
Total current liabilities	221.2	236.9
Long-term debt	359.3	371.3
Deferred income taxes	19.6	18.9
Pension and other postretirement benefits	79.1	83.1
Other long-term liabilities	52.9	55
Total Liabilities	732.1	765.2
Commitments and contingencies (Note 13)	'	'
Equity:	'	'
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0	0
Common stock, $0.25 par value; 100.0 million shares authorized; issued: 70.9 million and 70.4 million; outstanding: 70.8 million and 70.2 million	17.8	17.6
Capital in excess of par value	138.2	120
Retained earnings	855.5	805
Accumulated other comprehensive loss	-34.7	-32.4
Treasury stock, at cost (0.1 million and 0.2 million shares)	-4.2	-3.8
Total Equity	972.6	906.4
Total Liabilities and Equity	$1,704.70	$1,671.60

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, except Per Share data, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Preferred Stock, Shares Authorized	3	3
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$0.25	$0.25
Common Stock, Shares Authorized	100	100
Common Stock, Shares, Issued	70.9	70.4
Common Stock, Shares, Outstanding	70.8	70.2
Treasury Stock, Shares	0.1	0.2

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED) (USD $)	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]
In Millions, unless otherwise specified
Balance at Dec. 31, 2013	$906.40	$17.60	$120	($3.80)	$805	($32.40)
Balance (in shares) at Dec. 31, 2013	'	70.4	'	'	'	'
Increase (Decrease) in Equity [Roll Forward]	'	'	'	'	'	'
Net income	64.7	'	'	'	64.7	'
Stock-based compensation	8.6	'	9	-0.4	'	'
Shares issued under stock plans (shares)	'	0.6	'	'	'	'
Shares issued under stock plans	9.8	0.2	9.6	'	'	'
Shares repurchased for employee tax withholdings (shares)	'	-0.1	'	'	'	'
Shares repurchased for employee tax withholdings	-4.1	'	-4.1	'	'	'
Excess tax benefit from employee stock plans	3.7	'	3.7	'	'	'
Dividends declared	-14.2	'	'	'	-14.2	'
Other comprehensive loss, net of tax	-2.3	'	'	'	'	-2.3
Balance at Jun. 30, 2014	$972.60	$17.80	$138.20	($4.20)	$855.50	($34.70)
Balance (in shares) at Jun. 30, 2014	'	70.9	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$64.70	$61.90
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	42.6	39.1
Amortization	2.3	2.1
Loss on debt extinguishment	0	0.2
Stock-based compensation	8.9	10.4
Other non-cash items, net	-1.9	-2.7
Changes in assets and liabilities	-43.6	-12.6
Net cash provided by operating activities	73	98.4
Cash flows from investing activities:	'	'
Capital expenditures	-56.2	-83.8
Purchases of short-term investments	-9.3	-8.8
Sales and maturities of short-term investments	8.3	13.7
Other, net	0.2	-3
Net cash used in investing activities	-57	-81.9
Cash flows from financing activities:	'	'
Borrowings under revolving credit agreements	182.9	178.3
Repayments under revolving credit agreements	-192.9	-171.6
Issuance of long-term debt	0	43.3
Repayments of long-term debt	-1.1	-29.3
Dividend payments	-14.1	-13.1
Excess tax benefit from employee stock plans	3.7	1.1
Shares repurchased for employee tax withholdings	-4.1	-5.2
Proceeds from stock option exercises	5.2	10.7
Employee stock purchase plan contributions	1.5	1.1
Contingent consideration payments	-0.1	0
Net cash (used in) provided by financing activities	-19	15.3
Effect of exchange rates on cash	-0.3	-3.1
Net (decrease) increase in cash and cash equivalents	-3.3	28.7
Cash and cash equivalents at beginning of period	230	161.9
Cash and cash equivalents at end of period	$226.70	$190.60

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and six months ended June 30, 2014 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. (which may be referred to as “West”, “the Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2013 (“2013 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.
	Stock Split: On August 1, 2013, our Board of Directors approved a two-for-one stock split of our outstanding shares of common stock, effected in the form of a stock dividend. The record date for the stock split was September 12, 2013, and the share distribution occurred on September 26, 2013. All share and per share amounts presented in the accompanying condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the impact of this stock split.

New_Accounting_Standards

New Accounting Standards	6 Months Ended
	Jun. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New Accounting Standards	'
	New Accounting Standards
	Recently Adopted Standards
	In July 2013, the FASB issued revised guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. We adopted this guidance as of January 1, 2014, on a prospective basis. The adoption did not have a material impact on our financial statements.
	In March 2013, the FASB issued guidance that clarifies the application of U.S. GAAP to the release of cumulative translation adjustments related to changes of ownership in or within foreign entities, including step acquisitions. This guidance, which we adopted as of January 1, 2014, will be applied prospectively if and when changes of ownership related to foreign entities occur.
	Standards Issued Not Yet Adopted
	In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. In this case, the performance target would be required to be treated as a performance condition, and should not be reflected in estimating the grant-date fair value of the award. The guidance also addresses when to recognize the related compensation cost. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Management is currently reviewing this guidance to determine the impact it may have, if any, on our financial statements.
	In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2016. Entities can choose to apply the guidance using either the full retrospective approach or a modified retrospective approach. Management is currently evaluating the impact that this guidance will have on our financial statements, if any, including which transition method it will adopt.
	In April 2014, the FASB issued guidance for the reporting of discontinued operations, which also contains new disclosure requirements for both discontinued operations and other disposals that do not meet the definition of a discontinued operation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Management believes that the adoption of this guidance will not have a material impact on our financial statements.

Net_Income_Per_Share

Net Income Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Income Per Share	'
	Net Income Per Share
	The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
	(In millions)	2014		2013		2014		2013
	Numerator:
	Net income	$	37.6	$	30.2	$	64.7	$	61.9
	Denominator:
	Weighted average common shares outstanding	70.8		69.5		70.7		69.2
	Dilutive effect of stock options, stock appreciation rights and performance share awards, based on the treasury stock method	1.6		1.3		1.7		1.3
	Assumed conversion of convertible debt, based on the if-converted method	—		—		—		0.1
	Weighted average shares assuming dilution	72.4		70.8		72.4		70.6
	Under the "if-converted" method, the after-tax effect of interest expense related to convertible debt is added back to net income. During all periods presented, the add-back amount was immaterial.
	In addition, during the three months ended June 30, 2014 and 2013, there were 0.6 million and 0.9 million shares, respectively, not included in the computation of diluted net income per share, because their impact was antidilutive. There were 0.4 million and 0.6 million antidilutive options outstanding during the six months ended June 30, 2014 and 2013, respectively.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories are valued at the lower of cost (on a first-in, first-out basis) or market. Inventory balances were as follows:
	($ in millions)	June 30,		December 31,
		2014		2013
	Finished goods	$	80.5	$	80
	Work in process	31		24.8
	Raw materials	76.4		72.1
		$	187.9	$	176.9

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	The following table summarizes our long-term debt obligations, net of current maturities:
	($ in millions)	June 30,		December 31,
		2014		2013
	Term loan, due 2014	$	—	$	0.1
	Series B floating rate notes, due 2015	25		25
	Euro note B, due 2016	83.4		84.1
	Capital leases, due through 2016	0.3		0.4
	Revolving credit facility, due 2017	43.6		53.7
	Term loan, due 2018	40.3		41.3
	Note payable, due 2019	0.3		0.3
	Series A notes, due 2022	42		42
	Series B notes, due 2024	53		53
	Series C notes, due 2027	73		73
	Convertible debt, due 2047	0.6		0.6
		361.5		373.5
	Less: current portion of long-term debt	2.2		2.2
		$	359.3	$	371.3
	Please refer to Note 10, Debt, to the consolidated financial statements in our 2013 Annual Report for additional details regarding our debt agreements.
	At June 30, 2014, we had $43.6 million in outstanding borrowings under our multi-currency revolving credit facility, of which $4.9 million was denominated in Yen, $28.7 million in Euro and the remainder in U.S. dollar ("USD"). The total amount outstanding as of June 30, 2014 and December 31, 2013, was classified as long-term.
	At June 30, 2014, we had $40.3 million outstanding under our five-year term loan due January 2018, of which $2.1 million was classified as current. Please refer to Note 6, Derivative Financial Instruments, for a discussion of the interest-rate swap agreement associated with this loan.

Derivative_Financial_Instrumen

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	Derivative Financial Instruments
	Our ongoing business operations expose us to various risks such as fluctuating interest rates, foreign exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments such as interest rate swaps, options and foreign exchange contracts for periods consistent with and for notional amounts equal to or less than the related underlying exposures. We do not purchase or hold any derivative financial instruments for speculation or trading purposes. All derivatives are recorded on the balance sheet at fair value.
	Interest Rate Risk
	At June 30, 2014, we had $40.3 million of outstanding borrowings under our variable-rate five-year term loan related to the purchase of our new corporate office and research building. In anticipation of this debt, we entered into a forward-start interest rate swap to hedge the variability in cash flows due to changes in the applicable interest rate over the stated period. Under this swap, we receive variable interest rate payments based on one-month London Interbank Offering Rates (“LIBOR”) plus a margin in return for making monthly fixed interest payments at 5.41%. We designated this swap as a cash flow hedge.
	In addition, we have a $25.0 million interest rate swap agreement outstanding as of June 30, 2014, that is designated as a cash flow hedge to protect against volatility in the interest rates on our floating rate notes maturing on July 28, 2015 (“Series B Notes”). Under this swap, we receive variable interest rate payments based on three-month LIBOR in return for making quarterly fixed rate payments. Including the applicable margin, the interest rate swap agreement effectively fixes the interest rate payable on the Series B Notes at 5.51%.
	Foreign Exchange Rate Risk
	During 2014, we entered into several foreign currency hedge contracts that were designated as cash flow hedges of forecasted transactions denominated in foreign currencies, which are described in more detail below.
	We entered into a series of foreign currency contracts intended to hedge the currency risk associated with a portion of our forecasted Yen-denominated purchases of inventory from Daikyo Seiko Ltd. (“Daikyo”) made by West in the United States. As of June 30, 2014, there were six monthly contracts outstanding at ¥95.0 million ($0.9 million) each, for an aggregate notional amount of ¥570.0 million ($5.5 million).
	We also entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted USD-denominated inventory purchases made by certain European subsidiaries. As of June 30, 2014, there were six monthly contracts outstanding at a monthly amount ranging from $1.4 million to $3.0 million, for an aggregate notional amount of $14.1 million.
	Lastly, we entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted Euro-denominated sales of finished goods by one of our USD functional-currency subsidiaries. As of June 30, 2014, there were six monthly contracts outstanding at $1.5 million each, for an aggregate notional amount of $9.0 million.
	At June 30, 2014, a portion of our debt consists of borrowings denominated in currencies other than the U.S. dollar. We have designated our €61.1 million ($83.4 million) Euro note B and our €21.0 million ($28.7 million) Euro-denominated borrowings under our multi-currency revolving credit facility as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation loss of $4.7 million pre-tax ($2.9 million after tax) on this debt was recorded within accumulated other comprehensive loss as of June 30, 2014. We have also designated our ¥500.0 million ($4.9 million) Yen-denominated borrowings under our multi-currency revolving credit facility as a hedge of our net investment in Daikyo. At June 30, 2014, there was a cumulative foreign currency translation gain on this Yen-denominated debt of $0.5 million pre-tax ($0.3 million after tax) which was also included within accumulated other comprehensive loss.
	The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
		Amount of Gain (Loss) Recognized in OCI for						Amount of Loss Reclassified from Accumulated OCI into Income for				Location of Loss Reclassified from Accumulated OCI into Income
		Three Months Ended						Three Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014		2013
	Cash Flow Hedges:
	Foreign currency hedge contracts	$	0.1		$	(0.1	)	$	—	$	—	Net sales
	Foreign currency hedge contracts	0.2			(1.0		)	—		0.9		Cost of goods and services sold
	Interest rate swap contracts	(0.2		)	0.4			0.4		0.4		Interest expense
	Forward treasury locks	—			—			—		0.1		Interest expense
	Total	$	0.1		$	(0.7	)	$	0.4	$	1.4
	Net Investment Hedges:
	Foreign currency-denominated debt	$	0.5		$	(1.0	)	$	—	$	—	Other expense (income)
	Total	$	0.5		$	(1.0	)	$	—	$	—
		Amount of Gain (Loss) Recognized in OCI for						Amount of Loss Reclassified from Accumulated OCI into Income for				Location of Loss Reclassified from Accumulated OCI into Income
		Six Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014		2013
	Cash Flow Hedges:
	Foreign currency hedge contracts	$	—		$	0.2		$	—	$	—	Net sales
	Foreign currency hedge contracts	0.1			(2.7		)	—		1.5		Cost of goods and services sold
	Interest rate swap contracts	(0.3		)	0.5			0.8		0.8		Interest expense
	Forward treasury locks	—			—			0.1		0.1		Interest expense
	Total	$	(0.2	)	$	(2.0	)	$	0.9	$	2.4
	Net Investment Hedges:
	Foreign currency-denominated debt	$	0.5		$	1.4		$	—	$	—	Other expense (income)
	Total	$	0.5		$	1.4		$	—	$	—
	For the three and six months ended June 30, 2014 and 2013, there was no material ineffectiveness related to our hedges.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
	•	Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
	•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
	•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	The following tables present the assets and liabilities recorded at fair value on a recurring basis:
		Balance at			Basis of Fair Value Measurements
	($ in millions)	June 30,			Level 1		Level 2		Level 3
		2014
	Assets:
	Short-term investments	$	8.5		$	8.5	$	—	$	—
	Deferred compensation assets	6.1			6.1		—		—
	Foreign currency contracts	0.1			—		0.1		—
		$	14.7		$	14.6	$	0.1	$	—
	Liabilities:
	Contingent consideration	$	4.9		$	—	$	—	$	4.9
	Deferred compensation liabilities	7.7			7.7		—		—
	Interest rate swap contracts	4.7			—		4.7		—
	Foreign currency contracts	0.1			—		0.1		—
		$	17.4		$	7.7	$	4.8	$	4.9
		Balance at			Basis of Fair Value Measurements
	($ in millions)	December 31,			Level 1		Level 2		Level 3
		2013
	Assets:
	Short-term investments	$	7.5		$	7.5	$	—	$	—
	Deferred compensation assets	5.7			5.7		—		—
		$	13.2		$	13.2	$	—	$	—
	Liabilities:
	Contingent consideration	$	4.3		$	—	$	—	$	4.3
	Deferred compensation liabilities	7.8			7.8		—		—
	Interest rate swap contracts	5.6			—		5.6		—
		$	17.7		$	7.8	$	5.6	$	4.3
	Short-term investments, which are comprised of certificates of deposit and mutual funds, are included within other current assets and are valued using a market approach based on quoted market prices in an active market. Deferred compensation assets are included within other noncurrent assets and are also valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current assets and other current liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our contingent consideration is included within other current liabilities and other long-term liabilities and is discussed further in the section related to Level 3 measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Interest rate swap contracts, included within other long-term liabilities, are valued based on the terms of the contract and observable market inputs (i.e., LIBOR, Eurodollar synthetic forwards and swap spreads). Refer to Note 6, Derivative Financial Instruments, for further discussion of our derivatives.
	Level 3 Fair Value Measurements
	The fair value of the contingent consideration liability related to our SmartDoseTM electronic patch injector system (“SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of SmartDose progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the contingent consideration liability.
	The following table provides a summary of changes in our Level 3 fair value measurements:
		Six Months Ended
		June 30,
		2014			2013
	Beginning Balance	$	4.3		$	3.3
	Increase in fair value recorded in earnings	0.7			0.2
	Payments	(0.1		)	—
	Ending Balance	$	4.9		$	3.5
	Refer to Note 11, Other Expense, for further discussion of our acquisition-related contingency.
	Other Financial Instruments
	We believe that the carrying amounts of our cash and cash equivalents, accounts receivable and short-term borrowings approximate their fair values due to their near-term maturities.
	Quoted market prices are used to estimate the fair value of publicly traded long-term debt. The fair value of debt that is not quoted on an exchange is estimated using a discounted cash flow method based on interest rates that are currently available to us for debt issuances with similar terms and maturities. At June 30, 2014, the estimated fair value of long-term debt was $359.2 million compared to a carrying amount of $359.3 million. At December 31, 2013, the estimated fair value of long-term debt was $365.8 million and the carrying amount was $371.3 million.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss
	The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2014:
	($ in millions)	Losses on				Unrealized gains				Defined benefit				Foreign				Total
		cash flow				on investment				pension and other				currency
		hedges				securities				postretirement plans				translation
	Balance, December 31, 2013	$	(6.0	)		$	4.3			$	(47.0	)		$	16.3			$	(32.4	)
	Other comprehensive loss before reclassifications	(0.2		)		—				(0.4		)		(3.3		)		(3.9		)
	Amounts reclassified out	0.9				—				0.7				—				1.6
	Other comprehensive income (loss), net of tax	0.7				—				0.3				(3.3		)		(2.3		)
	Balance, June 30, 2014	$	(5.3	)		$	4.3			$	(46.7	)		$	13			$	(34.7	)
	A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
			Three Months Ended								Six Months Ended
			June 30,								June 30,
	Detail of components		2014				2013				2014				2013				Location on Statement of Income
	Losses on cash flow hedges:
	Foreign currency contracts		$	—			$	(1.4	)		$	—			$	(2.4	)		Cost of goods and services sold
	Interest rate swap contracts		(0.7		)		(0.7		)		(1.3		)		(1.3		)		Interest expense
	Forward treasury locks		—				(0.1		)		(0.2		)		(0.2		)		Interest expense
	Total before tax		(0.7		)		(2.2		)		(1.5		)		(3.9		)
	Tax expense		0.3				0.8				0.6				1.5
	Net of tax		$	(0.4	)		$	(1.4	)		$	(0.9	)		$	(2.4	)
	Amortization of defined benefit pension and other postretirement plans:
	Transition obligation		$	—			$	—			$	—			$	(0.1	)		(a)
	Prior service cost		0.3				0.3				0.6				0.7				(a)
	Actuarial losses		(0.8		)		(2.3		)		(1.6		)		(4.7		)		(a)
	Total before tax		(0.5		)		(2.0		)		(1.0		)		(4.1		)
	Tax expense		0.2				0.7				0.3				1.5
	Net of tax		$	(0.3	)		$	(1.3	)		$	(0.7	)		$	(2.6	)
	Total reclassifications for the period, net of tax		$	(0.7	)		$	(2.7	)		$	(1.6	)		$	(5.0	)
	(a)     These components are included in the computation of net periodic benefit cost. Refer to Note 10, Benefit Plans, for additional details.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	The 2011 Omnibus Incentive Compensation Plan (the "2011 Plan") provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. The terms and conditions of awards to be granted are determined by our Board's nominating and compensation committees. Vesting requirements vary by award. At June 30, 2014, there were 3,875,996 shares remaining in the 2011 Plan for future grants.
	During the six months ended June 30, 2014, we granted 597,093 stock options at a weighted average exercise price of $47.26 per share based on the grant-date fair value of our stock to key employees under the 2011 Plan. The weighted average grant date fair value of options granted was $10.35 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.57%; expected life of 6 years based on prior experience; stock volatility of 22.1% based on historical data; and a dividend yield of 0.8%. Stock option expense is recognized over the vesting period, net of forfeitures.
	In addition, during the six months ended June 30, 2014, we granted 130,486 performance vesting share (“PVS”) awards at a weighted grant-date fair value of $47.27 per share to key employees under the 2011 Plan. Each PVS award entitles the holder to one share of our common stock if the annual growth rate of revenue and return on invested capital targets are achieved over a three-year performance period. The actual payout may vary from 0% to 200% of an employee’s targeted award. The fair value of PVS awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.
	Total stock-based compensation expense was $4.6 million and $8.9 million for the three and six months ended June 30, 2014, respectively. For the three and six months ended June 30, 2013, total stock-based compensation expense was $5.0 million and $10.4 million, respectively.

Benefit_Plans

Benefit Plans	6 Months Ended
	Jun. 30, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]	'
Benefit Plans	'
	Benefit Plans
	The components of net periodic benefit cost for the three months ended June 30 were as follows ($ in millions):
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	Service cost	$	2.5		$	2.5		$	0.1		$	0.3	$	2.6		$	2.8
	Interest cost	4.3			3.7			0.1			0.3		4.4			4
	Expected return on assets	(4.8		)	(4.3		)	—			—		(4.8		)	(4.3		)
	Amortization of prior service credit	(0.3		)	(0.3		)	—			—		(0.3		)	(0.3		)
	Recognized actuarial losses (gains)	1.1			2.3			(0.3		)	—		0.8			2.3
	Net periodic benefit cost	$	2.8		$	3.9		$	(0.1	)	$	0.6	$	2.7		$	4.5
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	U.S. plans	$	2		$	3.1		$	(0.1	)	$	0.6	$	1.9		$	3.7
	International plans	0.8			0.8			—			—		0.8			0.8
	Net periodic benefit cost	$	2.8		$	3.9		$	(0.1	)	$	0.6	$	2.7		$	4.5
	The components of net periodic benefit cost for the six months ended June 30 were as follows ($ in millions):
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	Service cost	$	5.1		$	5		$	0.2		$	0.7	$	5.3		$	5.7
	Interest cost	8.5			7.4			0.2			0.5		8.7			7.9
	Expected return on assets	(9.7		)	(8.6		)	—			—		(9.7		)	(8.6		)
	Amortization of transition obligation	—			0.1			—			—		—			0.1
	Amortization of prior service credit	(0.6		)	(0.7		)	—			—		(0.6		)	(0.7		)
	Recognized actuarial losses (gains)	2.3			4.7			(0.7		)	—		1.6			4.7
	Net periodic benefit cost	$	5.6		$	7.9		$	(0.3	)	$	1.2	$	5.3		$	9.1
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	U.S. plans	$	4.1		$	6.3		$	(0.3	)	$	1.2	$	3.8		$	7.5
	International plans	1.5			1.6			—			—		1.5			1.6
	Net periodic benefit cost	$	5.6		$	7.9		$	(0.3	)	$	1.2	$	5.3		$	9.1

Other_Expense_Income

Other Expense (Income)	6 Months Ended
	Jun. 30, 2014
Other Income and Expenses [Abstract]	'
Other Expense (Income)	'
	Other expense (income) consists of:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014			2013
	Development income	$	(0.5	)	$	(0.5	)	$	(0.9	)	$	(0.8	)
	Acquisition-related contingencies	0.3			0.2			0.7			0.2
	Foreign exchange and other	0.5			(0.5		)	1.2			—
		$	0.3		$	(0.8	)	$	1		$	(0.6	)
	During the three and six months ended June 30, 2014, we recognized development income of $0.5 million and $0.9 million, respectively, within our Pharmaceutical Delivery Systems segment ("Delivery Systems"), most of which related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of SmartDose within a specific therapeutic area. As of June 30, 2014, there was $18.2 million of unearned income related to this payment, of which $1.5 million was included in other current liabilities and $16.7 million was included in other long-term liabilities. The unearned income is being recognized as development income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. During the three and six months ended June 30, 2013, we recorded development income of $0.5 million and $0.8 million, respectively, within Delivery Systems, of which $0.3 million related to the nonrefundable customer payment described above.
	During the three months ended June 30, 2014, the SmartDose contingent consideration increased by $0.3 million due to the time value of money. During the six months ended June 30, 2014, we increased the SmartDose contingent consideration by $0.7 million due to the time value of money and changes made to sales projections during the first quarter of 2014. The change in the SmartDose contingent consideration during both the three and six months ended June 30, 2013 was $0.2 million due to the time value of money and adjustments related to changes in sales projections. These adjustments are included within Delivery Systems' results.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. For both the three and six months ended June 30, 2014, our effective tax rate was 27.7%, compared with 26.5% and 24.2% for the same periods in 2013. The increase in the second-quarter effective tax rate primarily reflects the absence of the Research and Development ("R&D") tax credit in 2014 and changes in our geographic mix of earnings. The R&D tax credit was retroactively reinstated in January 2013 for two years, from January 1, 2012 through December 31, 2013, as a result of the enactment of the American Taxpayer Relief Act of 2012 (the "Taxpayer Relief Act"). The year-to-date effective tax rate increased due to the items mentioned above, as well as the impact of the $1.3 million discrete tax benefit recorded during the six months ended June 30, 2013 related to the R&D tax credit for activities completed in 2012. In accordance with U.S. GAAP, although the Taxpayer Relief Act reinstated the tax credit on a retroactive basis to January 1, 2012, the credit was not taken into account for financial reporting purposes until 2013.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.
	There have been no significant changes to the commitments and contingencies included in our 2013 Annual Report.

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Our business operations are organized into two reportable segments, which are aligned with the underlying markets and customers they serve. Our reportable segments are the Pharmaceutical Packaging Systems segment (“Packaging Systems”) and Delivery Systems. Packaging Systems develops, manufactures and sells primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and a variety of custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of our line of proprietary, multi-component systems for injectable drug administration and other healthcare applications.
	Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
	The following table presents information about our reportable segments, reconciled to consolidated totals:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014			2013
	Net sales:
	Packaging Systems	$	268		$	251.5		$	520.9		$	503
	Delivery Systems	101.1			93.3			195.1			181.5
	Intersegment sales	(0.2		)	(0.3		)	(0.3		)	(0.6		)
	Total net sales	$	368.9		$	344.5		$	715.7		$	683.9
	Operating profit:
	Packaging Systems	$	62.9		$	56.8		$	114.3		$	115.5
	Delivery Systems	3.7			2.3			3.5			3.5
	Corporate	(12.5		)	(16.6		)	(24.4		)	(33.1		)
	Total operating profit	$	54.1		$	42.5		$	93.4		$	85.9
	Loss on debt extinguishment	—			—			—			0.2
	Interest expense	4.2			4.1			8.2			8.7
	Interest income	0.5			0.4			0.9			1
	Income before income taxes	$	50.4		$	38.8		$	86.1		$	78
	The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and six months ended June 30, 2014 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. (which may be referred to as “West”, “the Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2013 (“2013 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.
Stock Split	'
	Stock Split: On August 1, 2013, our Board of Directors approved a two-for-one stock split of our outstanding shares of common stock, effected in the form of a stock dividend. The record date for the stock split was September 12, 2013, and the share distribution occurred on September 26, 2013. All share and per share amounts presented in the accompanying condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the impact of this stock split.
New Accounting Standards	'
	Recently Adopted Standards
	In July 2013, the FASB issued revised guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. We adopted this guidance as of January 1, 2014, on a prospective basis. The adoption did not have a material impact on our financial statements.
	In March 2013, the FASB issued guidance that clarifies the application of U.S. GAAP to the release of cumulative translation adjustments related to changes of ownership in or within foreign entities, including step acquisitions. This guidance, which we adopted as of January 1, 2014, will be applied prospectively if and when changes of ownership related to foreign entities occur.
	Standards Issued Not Yet Adopted
	In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. In this case, the performance target would be required to be treated as a performance condition, and should not be reflected in estimating the grant-date fair value of the award. The guidance also addresses when to recognize the related compensation cost. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Management is currently reviewing this guidance to determine the impact it may have, if any, on our financial statements.
	In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2016. Entities can choose to apply the guidance using either the full retrospective approach or a modified retrospective approach. Management is currently evaluating the impact that this guidance will have on our financial statements, if any, including which transition method it will adopt.
	In April 2014, the FASB issued guidance for the reporting of discontinued operations, which also contains new disclosure requirements for both discontinued operations and other disposals that do not meet the definition of a discontinued operation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Management believes that the adoption of this guidance will not have a material impact on our financial statements.

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Reconciliation of Basic to Diluted Net Income Per Share	'
	The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
	(In millions)	2014		2013		2014		2013
	Numerator:
	Net income	$	37.6	$	30.2	$	64.7	$	61.9
	Denominator:
	Weighted average common shares outstanding	70.8		69.5		70.7		69.2
	Dilutive effect of stock options, stock appreciation rights and performance share awards, based on the treasury stock method	1.6		1.3		1.7		1.3
	Assumed conversion of convertible debt, based on the if-converted method	—		—		—		0.1
	Weighted average shares assuming dilution	72.4		70.8		72.4		70.6

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories are valued at the lower of cost (on a first-in, first-out basis) or market. Inventory balances were as follows:
	($ in millions)	June 30,		December 31,
		2014		2013
	Finished goods	$	80.5	$	80
	Work in process	31		24.8
	Raw materials	76.4		72.1
		$	187.9	$	176.9

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long-term Debt Obligations, Net of Current Maturities	'
	The following table summarizes our long-term debt obligations, net of current maturities:
	($ in millions)	June 30,		December 31,
		2014		2013
	Term loan, due 2014	$	—	$	0.1
	Series B floating rate notes, due 2015	25		25
	Euro note B, due 2016	83.4		84.1
	Capital leases, due through 2016	0.3		0.4
	Revolving credit facility, due 2017	43.6		53.7
	Term loan, due 2018	40.3		41.3
	Note payable, due 2019	0.3		0.3
	Series A notes, due 2022	42		42
	Series B notes, due 2024	53		53
	Series C notes, due 2027	73		73
	Convertible debt, due 2047	0.6		0.6
		361.5		373.5
	Less: current portion of long-term debt	2.2		2.2
		$	359.3	$	371.3

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings	'
	The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
		Amount of Gain (Loss) Recognized in OCI for						Amount of Loss Reclassified from Accumulated OCI into Income for				Location of Loss Reclassified from Accumulated OCI into Income
		Three Months Ended						Three Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014		2013
	Cash Flow Hedges:
	Foreign currency hedge contracts	$	0.1		$	(0.1	)	$	—	$	—	Net sales
	Foreign currency hedge contracts	0.2			(1.0		)	—		0.9		Cost of goods and services sold
	Interest rate swap contracts	(0.2		)	0.4			0.4		0.4		Interest expense
	Forward treasury locks	—			—			—		0.1		Interest expense
	Total	$	0.1		$	(0.7	)	$	0.4	$	1.4
	Net Investment Hedges:
	Foreign currency-denominated debt	$	0.5		$	(1.0	)	$	—	$	—	Other expense (income)
	Total	$	0.5		$	(1.0	)	$	—	$	—
		Amount of Gain (Loss) Recognized in OCI for						Amount of Loss Reclassified from Accumulated OCI into Income for				Location of Loss Reclassified from Accumulated OCI into Income
		Six Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014		2013
	Cash Flow Hedges:
	Foreign currency hedge contracts	$	—		$	0.2		$	—	$	—	Net sales
	Foreign currency hedge contracts	0.1			(2.7		)	—		1.5		Cost of goods and services sold
	Interest rate swap contracts	(0.3		)	0.5			0.8		0.8		Interest expense
	Forward treasury locks	—			—			0.1		0.1		Interest expense
	Total	$	(0.2	)	$	(2.0	)	$	0.9	$	2.4
	Net Investment Hedges:
	Foreign currency-denominated debt	$	0.5		$	1.4		$	—	$	—	Other expense (income)
	Total	$	0.5		$	1.4		$	—	$	—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Assets and Liabilities Measured at Fair Value	'
	The following tables present the assets and liabilities recorded at fair value on a recurring basis:
		Balance at			Basis of Fair Value Measurements
	($ in millions)	June 30,			Level 1		Level 2		Level 3
		2014
	Assets:
	Short-term investments	$	8.5		$	8.5	$	—	$	—
	Deferred compensation assets	6.1			6.1		—		—
	Foreign currency contracts	0.1			—		0.1		—
		$	14.7		$	14.6	$	0.1	$	—
	Liabilities:
	Contingent consideration	$	4.9		$	—	$	—	$	4.9
	Deferred compensation liabilities	7.7			7.7		—		—
	Interest rate swap contracts	4.7			—		4.7		—
	Foreign currency contracts	0.1			—		0.1		—
		$	17.4		$	7.7	$	4.8	$	4.9
		Balance at			Basis of Fair Value Measurements
	($ in millions)	December 31,			Level 1		Level 2		Level 3
		2013
	Assets:
	Short-term investments	$	7.5		$	7.5	$	—	$	—
	Deferred compensation assets	5.7			5.7		—		—
		$	13.2		$	13.2	$	—	$	—
	Liabilities:
	Contingent consideration	$	4.3		$	—	$	—	$	4.3
	Deferred compensation liabilities	7.8			7.8		—		—
	Interest rate swap contracts	5.6			—		5.6		—
		$	17.7		$	7.8	$	5.6	$	4.3
Summary of Changes in Level 3 Fair Value Measurements	'
	The following table provides a summary of changes in our Level 3 fair value measurements:
		Six Months Ended
		June 30,
		2014			2013
	Beginning Balance	$	4.3		$	3.3
	Increase in fair value recorded in earnings	0.7			0.2
	Payments	(0.1		)	—
	Ending Balance	$	4.9		$	3.5

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Components of Accumulated Other Comprehensive Loss	'
	The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2014:
	($ in millions)	Losses on				Unrealized gains				Defined benefit				Foreign				Total
		cash flow				on investment				pension and other				currency
		hedges				securities				postretirement plans				translation
	Balance, December 31, 2013	$	(6.0	)		$	4.3			$	(47.0	)		$	16.3			$	(32.4	)
	Other comprehensive loss before reclassifications	(0.2		)		—				(0.4		)		(3.3		)		(3.9		)
	Amounts reclassified out	0.9				—				0.7				—				1.6
	Other comprehensive income (loss), net of tax	0.7				—				0.3				(3.3		)		(2.3		)
	Balance, June 30, 2014	$	(5.3	)		$	4.3			$	(46.7	)		$	13			$	(34.7	)
Reclassification out of Accumulated Other Comprehensive Loss	'
	A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
			Three Months Ended								Six Months Ended
			June 30,								June 30,
	Detail of components		2014				2013				2014				2013				Location on Statement of Income
	Losses on cash flow hedges:
	Foreign currency contracts		$	—			$	(1.4	)		$	—			$	(2.4	)		Cost of goods and services sold
	Interest rate swap contracts		(0.7		)		(0.7		)		(1.3		)		(1.3		)		Interest expense
	Forward treasury locks		—				(0.1		)		(0.2		)		(0.2		)		Interest expense
	Total before tax		(0.7		)		(2.2		)		(1.5		)		(3.9		)
	Tax expense		0.3				0.8				0.6				1.5
	Net of tax		$	(0.4	)		$	(1.4	)		$	(0.9	)		$	(2.4	)
	Amortization of defined benefit pension and other postretirement plans:
	Transition obligation		$	—			$	—			$	—			$	(0.1	)		(a)
	Prior service cost		0.3				0.3				0.6				0.7				(a)
	Actuarial losses		(0.8		)		(2.3		)		(1.6		)		(4.7		)		(a)
	Total before tax		(0.5		)		(2.0		)		(1.0		)		(4.1		)
	Tax expense		0.2				0.7				0.3				1.5
	Net of tax		$	(0.3	)		$	(1.3	)		$	(0.7	)		$	(2.6	)
	Total reclassifications for the period, net of tax		$	(0.7	)		$	(2.7	)		$	(1.6	)		$	(5.0	)
	(a)     These components are included in the computation of net periodic benefit cost. Refer to Note 10, Benefit Plans, for additional details.

Benefit_Plans_Tables

Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]	'
Schedule of Components of Net Periodic Benefit Cost	'
	The components of net periodic benefit cost for the three months ended June 30 were as follows ($ in millions):
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	Service cost	$	2.5		$	2.5		$	0.1		$	0.3	$	2.6		$	2.8
	Interest cost	4.3			3.7			0.1			0.3		4.4			4
	Expected return on assets	(4.8		)	(4.3		)	—			—		(4.8		)	(4.3		)
	Amortization of prior service credit	(0.3		)	(0.3		)	—			—		(0.3		)	(0.3		)
	Recognized actuarial losses (gains)	1.1			2.3			(0.3		)	—		0.8			2.3
	Net periodic benefit cost	$	2.8		$	3.9		$	(0.1	)	$	0.6	$	2.7		$	4.5
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	U.S. plans	$	2		$	3.1		$	(0.1	)	$	0.6	$	1.9		$	3.7
	International plans	0.8			0.8			—			—		0.8			0.8
	Net periodic benefit cost	$	2.8		$	3.9		$	(0.1	)	$	0.6	$	2.7		$	4.5
	The components of net periodic benefit cost for the six months ended June 30 were as follows ($ in millions):
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	Service cost	$	5.1		$	5		$	0.2		$	0.7	$	5.3		$	5.7
	Interest cost	8.5			7.4			0.2			0.5		8.7			7.9
	Expected return on assets	(9.7		)	(8.6		)	—			—		(9.7		)	(8.6		)
	Amortization of transition obligation	—			0.1			—			—		—			0.1
	Amortization of prior service credit	(0.6		)	(0.7		)	—			—		(0.6		)	(0.7		)
	Recognized actuarial losses (gains)	2.3			4.7			(0.7		)	—		1.6			4.7
	Net periodic benefit cost	$	5.6		$	7.9		$	(0.3	)	$	1.2	$	5.3		$	9.1
		Pension benefits						Other retirement benefits					Total
		2014			2013			2014			2013		2014			2013
	U.S. plans	$	4.1		$	6.3		$	(0.3	)	$	1.2	$	3.8		$	7.5
	International plans	1.5			1.6			—			—		1.5			1.6
	Net periodic benefit cost	$	5.6		$	7.9		$	(0.3	)	$	1.2	$	5.3		$	9.1

Other_Expense_Income_Tables

Other Expense (Income) (Tables)	6 Months Ended
	Jun. 30, 2014
Other Income and Expenses [Abstract]	'
Schedule of Other Expense (Income)	'
	Other expense (income) consists of:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014			2013
	Development income	$	(0.5	)	$	(0.5	)	$	(0.9	)	$	(0.8	)
	Acquisition-related contingencies	0.3			0.2			0.7			0.2
	Foreign exchange and other	0.5			(0.5		)	1.2			—
		$	0.3		$	(0.8	)	$	1		$	(0.6	)

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	The following table presents information about our reportable segments, reconciled to consolidated totals:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	($ in millions)	2014			2013			2014			2013
	Net sales:
	Packaging Systems	$	268		$	251.5		$	520.9		$	503
	Delivery Systems	101.1			93.3			195.1			181.5
	Intersegment sales	(0.2		)	(0.3		)	(0.3		)	(0.6		)
	Total net sales	$	368.9		$	344.5		$	715.7		$	683.9
	Operating profit:
	Packaging Systems	$	62.9		$	56.8		$	114.3		$	115.5
	Delivery Systems	3.7			2.3			3.5			3.5
	Corporate	(12.5		)	(16.6		)	(24.4		)	(33.1		)
	Total operating profit	$	54.1		$	42.5		$	93.4		$	85.9
	Loss on debt extinguishment	—			—			—			0.2
	Interest expense	4.2			4.1			8.2			8.7
	Interest income	0.5			0.4			0.9			1
	Income before income taxes	$	50.4		$	38.8		$	86.1		$	78

Net_Income_Per_Share_Details

Net Income Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income	$37.60	$30.20	$64.70	$61.90
Weighted average common shares outstanding (in shares)	70.8	69.5	70.7	69.2
Dilutive effect of stock options, stock appreciation rights and performance share awards, based on the treasury stock method (in shares)	1.6	1.3	1.7	1.3
Assumed conversion of convertible debt, based on the if-converted method (in shares)	0	0	0	0.1
Weighted average shares assuming dilution (in shares)	72.4	70.8	72.4	70.6
Antidilutive options excluded from computation of diluted net income per share (in shares)	0.6	0.9	0.4	0.6

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished goods	$80.50	$80
Work in process	31	24.8
Raw materials	76.4	72.1
Total inventories	$187.90	$176.90

Debt_Details

Debt (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term debt	$361.50	$373.50
Notes payable and other current debt	2.2	2.2
Long-term debt, excluding current portion	359.3	371.3
Term Loan Due 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	0	0.1
Series B Floating Rate Notes Due 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	25	25
Euro Note B Due 2016 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	83.4	84.1
Capital leases, due through 2016 [Member]	'	'
Debt Instrument [Line Items]	'	'
Capital leases	0.3	0.4
Revolving credit facility, due 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	43.6	53.7
Line of credit facility outstanding borrowings, Yen	4.9	'
Line of credit facility outstanding borrowings, Euro	28.7	'
Term Loan Due 2018 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	40.3	41.3
Current portion of long-term debt	2.1	'
Debt Instrument Term	'5 years 0 months 0 days	'
Notes Payable due 2019 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	0.3	0.3
Series A Notes, Due 2022 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	42	42
Series B Notes, Due 2024 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	53	53
Series C Notes, Due 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	73	73
Convertible Debt Due 2047 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	$0.60	$0.60

Derivative_Financial_Instrumen2

Derivative Financial Instruments (Details)

6 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Forward-Start Interest Rate Swap [Member]

Interest Rate Swap, Series B Note [Member]

Foreign Currency Hedge, Euro-Denominated Sales [Member]

Foreign Currency Hedge, Yen-denominated Inventory Purchases

Foreign Currency Hedge, Yen-denominated Inventory Purchases

Foreign Currency Hedge, USD-denominated Inventory Purchases

Euro-Denominated Revolver [Member]

Euro-Denominated Revolver [Member]

Yen-Denominated Revolver [Member]

Yen-Denominated Revolver [Member]

Euro Note B [Member]

Euro Note B [Member]

Euro-Denominated Debt [Member]

USD ($)

USD ($)

USD ($)

USD ($)

JPY (¥)

USD ($)

USD ($)

EUR (€)

USD ($)

JPY (¥)

USD ($)

EUR (€)

USD ($)

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount

'

$25

$1.50

$0.90

¥ 95

'

'

'

'

'

'

'

'

Amount of hedged item

40.3

'

'

'

'

'

'

'

'

'

'

'

'

Maximum term (in years)

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest rate

5.41%

5.51%

'

'

'

'

'

'

'

'

'

'

'

Maturity date of debt

'

28-Jul-15

'

'

'

'

'

'

'

'

'

'

'

Variable rate basis

'one-month London Interbank Offering Rates (bLIBORb)

'three-month LIBOR

'

'

'

'

'

'

'

'

'

'

'

Number of monthly contracts remaining

'

'

6

6

6

6

'

'

'

'

'

'

'

Monthly notional amount, minimum

'

'

'

'

'

1.4

'

'

'

'

'

'

'

Monthly notional amount, maximum

'

'

'

'

'

3

'

'

'

'

'

'

'

Aggregate notional amount of remaining contracts

'

'

9

5.5

570

14.1

'

'

'

'

'

'

'

Notional amount, nonderivative instruments

'

'

'

'

'

'

28.7

21

4.9

500

83.4

61.1

'

Cumulative foreign currency translation loss (gain)

'

'

'

'

'

'

'

'

-0.5

'

'

'

4.7

Cumulative foreign currency translation loss (gain), net of tax

'

'

'

'

'

'

'

'

($0.30)

'

'

'

$2.90

Effects_of_Derivative_Instrume

Effects of Derivative Instruments on OCI and Earnings (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Cash Flow Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	$0.10	($0.70)	($0.20)	($2)
Amount of Loss Reclassified from Accumulated OCI into Income	0.4	1.4	0.9	2.4
Net Investment Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	0.5	-1	0.5	1.4
Amount of Loss Reclassified from Accumulated OCI into Income	0	0	0	0
Foreign Currency Hedge Contracts [Member] | Net Sales [Member] | Cash Flow Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	0.1	-0.1	0	0.2
Amount of Loss Reclassified from Accumulated OCI into Income	0	0	0	0
Foreign Currency Hedge Contracts [Member] | Cost of Goods and Services Sold [Member] | Cash Flow Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	0.2	-1	0.1	-2.7
Amount of Loss Reclassified from Accumulated OCI into Income	0	0.9	0	1.5
Interest Rate Swap Contracts [Member] | Interest Expense [Member] | Cash Flow Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	-0.2	0.4	-0.3	0.5
Amount of Loss Reclassified from Accumulated OCI into Income	0.4	0.4	0.8	0.8
Forward Treasury Locks [Member] | Interest Expense [Member] | Cash Flow Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	0	0	0	0
Amount of Loss Reclassified from Accumulated OCI into Income	0	0.1	0.1	0.1
Foreign Currency - Denominated Debt [Member] | Other Expense (Income) [Member] | Net Investment Hedges [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain (Loss) Recognized in OCI	0.5	-1	0.5	1.4
Amount of Loss Reclassified from Accumulated OCI into Income	$0	$0	$0	$0

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets:	'	'
Short-term investments	$8.50	$7.50
Deferred compensation assets	6.1	5.7
Foreign currency contracts	0.1	'
Total assets at fair value	14.7	13.2
Liabilities:	'	'
Contingent consideration	4.9	4.3
Deferred compensation liabilities	7.7	7.8
Interest rate swap contracts	4.7	5.6
Foreign currency contracts	0.1	'
Total liabilities at fair value	17.4	17.7
Level 1 [Member]	'	'
Assets:	'	'
Short-term investments	8.5	7.5
Deferred compensation assets	6.1	5.7
Total assets at fair value	14.6	13.2
Liabilities:	'	'
Deferred compensation liabilities	7.7	7.8
Total liabilities at fair value	7.7	7.8
Level 2 [Member]	'	'
Assets:	'	'
Foreign currency contracts	0.1	'
Total assets at fair value	0.1	'
Liabilities:	'	'
Interest rate swap contracts	4.7	5.6
Foreign currency contracts	0.1	'
Total liabilities at fair value	4.8	5.6
Level 3 [Member]	'	'
Liabilities:	'	'
Contingent consideration	4.9	4.3
Total liabilities at fair value	$4.90	$4.30

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Level 3 Fair Value Measurements [Roll Forward]	'	'
Balance, beginning of period	$4.30	$3.30
Increase in fair value recorded in earnings	0.7	0.2
Payments	-0.1	'
Balance, end of period	$4.90	$3.50

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Other Financial Instruments [Abstract]	'	'
Long-term debt, fair value	$359.20	$365.80
Long-term debt	$359.30	$371.30

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]	'	'	'	'
Balance, beginning	'	'	($32.40)	'
Other comprehensive loss before reclassifications	'	'	-3.9	'
Amounts reclassified out	'	'	1.6	'
Other comprehensive (loss) income, net of tax	-0.9	1	-2.3	-15.5
Balance, ending	-34.7	'	-34.7	'
Losses on Cash Flow Hedges [Member]	'	'	'	'
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]	'	'	'	'
Balance, beginning	'	'	-6	'
Other comprehensive loss before reclassifications	'	'	-0.2	'
Amounts reclassified out	'	'	0.9	'
Other comprehensive (loss) income, net of tax	'	'	0.7	'
Balance, ending	-5.3	'	-5.3	'
Unrealized Gains on Investment Securities [Member]	'	'	'	'
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]	'	'	'	'
Balance, beginning	'	'	4.3	'
Other comprehensive loss before reclassifications	'	'	0	'
Amounts reclassified out	'	'	0	'
Other comprehensive (loss) income, net of tax	'	'	0	'
Balance, ending	4.3	'	4.3	'
Defined Benefit Pension and Other Postretirement Plans [Member]	'	'	'	'
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]	'	'	'	'
Balance, beginning	'	'	-47	'
Other comprehensive loss before reclassifications	'	'	-0.4	'
Amounts reclassified out	'	'	0.7	'
Other comprehensive (loss) income, net of tax	'	'	0.3	'
Balance, ending	-46.7	'	-46.7	'
Foreign Currency Translation [Member]	'	'	'	'
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]	'	'	'	'
Balance, beginning	'	'	16.3	'
Other comprehensive loss before reclassifications	'	'	-3.3	'
Amounts reclassified out	'	'	0	'
Other comprehensive (loss) income, net of tax	'	'	-3.3	'
Balance, ending	$13	'	$13	'

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Loss (Details 1) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Cost of goods and services sold	$247.10		$233.60		$487.50		$461.30
Interest expense	4.2		4.1		8.2		8.7
Transition Obligation	'		'		0		0.1
Prior service cost	0.3		0.3		0.6		0.7
Actuarial losses	-0.8		-2.3		-1.6		-4.7
Income before income taxes	50.4		38.8		86.1		78
Tax expense	-14		-10.3		-23.8		-18.9
Net income	37.6		30.2		64.7		61.9
Reclassification out of Accumulated Other Comprehensive Loss [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Net income	-0.7		-2.7		-1.6		-5
Reclassification out of Accumulated Other Comprehensive Loss [Member] | Losses on Cash Flow Hedges [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Income before income taxes	-0.7		-2.2		-1.5		-3.9
Tax expense	0.3		0.8		0.6		1.5
Net income	-0.4		-1.4		-0.9		-2.4
Reclassification out of Accumulated Other Comprehensive Loss [Member] | Amortization of Defined Benefit Pension and Other Postretirement Plans [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Transition Obligation	0	[1]	0	[1]	0	[1]	-0.1	[1]
Prior service cost	0.3	[1]	0.3	[1]	0.6	[1]	0.7	[1]
Actuarial losses	-0.8	[1]	-2.3	[1]	-1.6	[1]	-4.7	[1]
Income before income taxes	-0.5		-2		-1		-4.1
Tax expense	0.2		0.7		0.3		1.5
Net income	-0.3		-1.3		-0.7		-2.6
Foreign Currency Contract [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Losses on Cash Flow Hedges [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Cost of goods and services sold	0		-1.4		0		-2.4
Interest Rate Swap Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Losses on Cash Flow Hedges [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Interest expense	-0.7		-0.7		-1.3		-1.3
Forward Treasury Locks [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Losses on Cash Flow Hedges [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]	'		'		'		'
Interest expense	$0		($0.10)		($0.20)		($0.20)
[1]	These components are included in the computation of net periodic benefit cost. Refer to Note 10, Benefit Plans, for additional details.

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Shares available for issuance under the 2011 Plan (in shares)	3,875,996	'	3,875,996	'
Stock options, granted (in shares)	'	'	597,093	'
Stock options, weighted average exercise price (in dollars per share)	'	'	$47.26	'
Stock options, weighted average grant date fair value (in dollars per share)	'	'	$10.35	'
Assumptions used in Black-Scholes model	'	'	'	'
Risk-free interest rate (in hundredths)	'	'	1.57%	'
Expected life (in years)	'	'	'6 years 0 months 0 days	'
Stock volatility (in hundredths)	'	'	22.10%	'
Dividend yield (in hundredths)	'	'	0.80%	'
Granted, PVS awards (in shares)	'	'	130,486	'
Grant date fair value, PVS awards (in dollars per share)	'	'	$47.27	'
Number of shares of common stock per PVS award (in shares)	1	'	1	'
Performance period	'	'	'3 years	'
PVS payout, Minimum (in hundredths)	0.00%	'	0.00%	'
PVS payout, Maximum (in hundredths)	200.00%	'	200.00%	'
Stock-based compensation expense	$4.60	$5	$8.90	$10.40

Benefit_Plans_Details

Benefit Plans (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Service cost	$2.60	$2.80	$5.30	$5.70
Interest cost	4.4	4	8.7	7.9
Expected return on assets	-4.8	-4.3	-9.7	-8.6
Amortization of transition obligation	'	'	0	0.1
Amortization of prior service credit	-0.3	-0.3	-0.6	-0.7
Recognized actuarial losses (gains)	0.8	2.3	1.6	4.7
Net periodic benefit cost	2.7	4.5	5.3	9.1
Pension Benefits [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Service cost	2.5	2.5	5.1	5
Interest cost	4.3	3.7	8.5	7.4
Expected return on assets	-4.8	-4.3	-9.7	-8.6
Amortization of transition obligation	'	'	0	0.1
Amortization of prior service credit	-0.3	-0.3	-0.6	-0.7
Recognized actuarial losses (gains)	1.1	2.3	2.3	4.7
Net periodic benefit cost	2.8	3.9	5.6	7.9
Other Retirement Benefits [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Service cost	0.1	0.3	0.2	0.7
Interest cost	0.1	0.3	0.2	0.5
Expected return on assets	0	0	0	0
Amortization of transition obligation	'	'	0	0
Amortization of prior service credit	0	0	0	0
Recognized actuarial losses (gains)	-0.3	0	-0.7	0
Net periodic benefit cost	-0.1	0.6	-0.3	1.2
U.S. Pension Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	2	3.1	4.1	6.3
International Pension Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	0.8	0.8	1.5	1.6
U.S. Other Retirement Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	-0.1	0.6	-0.3	1.2
International Other Retirement Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	0	0	0	0
U.S. Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	1.9	3.7	3.8	7.5
International Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'	'
Net periodic benefit cost	$0.80	$0.80	$1.50	$1.60

Other_Expense_Income_Details

Other Expense (Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Other Income and Expenses [Abstract]	'	'	'	'
Development Income	($0.50)	($0.50)	($0.90)	($0.80)
Acquisition-related contingencies	0.3	0.2	0.7	0.2
Foreign exchange and other	0.5	-0.5	1.2	0
Other expense (income)	$0.30	($0.80)	$1	($0.60)

Other_Expense_Income_Details_1

Other Expense (Income) (Details 1) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Other Income and Expenses [Abstract]	'	'	'	'
Increase in SmartDose contingent consideration	$0.30	$0.20	$0.70	$0.20
Recognition of income related to nonrefundable payment	'	0.3	'	0.3
Nonrefundable payment from customer	18.2	20	18.2	20
Unearned income, current	1.5	'	1.5	'
Unearned income, noncurrent	16.7	'	16.7	'
Development Income	$0.50	$0.50	$0.90	$0.80

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective tax rate (in hundredths)	27.70%	26.50%	27.70%	24.20%
Discrete tax benefit, R&D credit	'	'	'	$1.30

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Reportable segments	'	'	2	'
Net sales	$368.90	$344.50	$715.70	$683.90
Operating profit	54.1	42.5	93.4	85.9
Loss on debt extinguishment	0	0	0	0.2
Interest expense	4.2	4.1	8.2	8.7
Interest income	0.5	0.4	0.9	1
Income before income taxes	50.4	38.8	86.1	78
Packaging Systems [Member]	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Net sales	268	251.5	520.9	503
Operating profit	62.9	56.8	114.3	115.5
Delivery Systems [Member]	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Net sales	101.1	93.3	195.1	181.5
Operating profit	3.7	2.3	3.5	3.5
Intersegment Sales [Member]	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Net sales	-0.2	-0.3	-0.3	-0.6
Corporate [Member]	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating profit	($12.50)	($16.60)	($24.40)	($33.10)